Eli Lilly launches oral weight-loss drug Foundayo in UK market

Eli Lilly has introduced its oral weight-loss treatment, Foundayo, in the United Kingdom, marking the first commercial availability of the drug in Europe. The launch represents a significant expansion of the company's obesity portfolio, though the long-term impact on regional market share and supply chain capacity remains to be determined.